CLINICAL TRIALS PROFILE FOR CLARITIN HIVES RELIEF
✉ Email this page to a colleague
All Clinical Trials for CLARITIN HIVES RELIEF
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00550550 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) | Completed | ALK-Abelló A/S | Phase 3 | 2007-11-01 | The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma. |
| NCT00550550 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-11-01 | The purpose of the study is to investigate the efficacy and safety of a grass sublingual tablet in children and adolescents with a history of grass-pollen induced rhinoconjunctivitis with or without asthma. |
| NCT00562159 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) | Completed | ALK-Abelló A/S | Phase 3 | 2007-11-01 | This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet. |
| NCT00562159 ↗ | Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | Phase 3 | 2007-11-01 | This purpose of this study is to determine the efficacy and safety of a grass sublingual (under-the-tongue) tablet. |
| NCT00730912 ↗ | Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539) | Completed | Merck Sharp & Dohme Corp. | Phase 4 | 2008-06-01 | This is a post marketing study to confirm the appropriate dose of loratadine in children by obtaining drug concentration data at multiple time points per child and adult patient, after the patient receives repeated administrations of the approved dose of loratadine. |
| NCT00762983 ↗ | Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED) | Completed | Merck Sharp & Dohme Corp. | 2008-03-01 | The purpose of this study is to collect information on unexpected adverse reactions (ADRs), how often ADRs occur, and factors that can affect the safety and effectiveness of Claritin (loratadine) when used in children. Patients will be observed while they are taking Claritin, and ADRs and symptom scores will be recorded. At the end of treatment, improvement in symptoms will be recorded. Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws. | |
| NCT00776217 ↗ | Bioequivalence Study on Loratadine Orally Disintegrating Tablets 10 mg Under Fasting Conditions | Completed | Ranbaxy Laboratories Limited | N/A | 2006-06-01 | To compare the single-dose oral bioavailability of loratadine 10 mg orally disintegrating tablets of Ohm Laboratories (a subsidiary of Ranbaxy Pharmaceuticals Inc., USA) with Claritin® Reditabs® (containing loratadine 10 mg) of Schering-Plough Healthcare Product Inc., USA in healthy, adult, human male subjects under fasting condition. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for CLARITIN HIVES RELIEF
Condition Name
Clinical Trial Locations for CLARITIN HIVES RELIEF
Trials by Country
Clinical Trial Progress for CLARITIN HIVES RELIEF
Clinical Trial Phase
Clinical Trial Sponsors for CLARITIN HIVES RELIEF
Sponsor Name
